Skip to main content
Clinical Trials/NCT01317836
NCT01317836
Completed
Not Applicable

PET-CT in Diagnosis of Pancreatic Cystic Neoplasms

Turku University Hospital1 site in 1 country31 target enrollmentMarch 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Neoplasms
Sponsor
Turku University Hospital
Enrollment
31
Locations
1
Primary Endpoint
Predictive Value of PET/CT imaging for Identifying Malignant and Benign Pancreatic Cystic Lesions
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Preoperative diagnosis of pancreatic cystic lesions remains a difficult problem in clinical practice. At present, the treatment planning in pancreatic cystic neoplasms is significantly restricted by the limited preoperative diagnosis. Ultrasonography (US), multidetector computed tomography (MDCT) and magnetic resonance imaging (MRI) are the conventional modalities in imaging of pancreatic cystic neoplasms, but by these methods the diagnostic accuracy still remains compromised. Furthermore, recently encouraging results have been obtained in pancreatic cystic neoplasms using 18F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG-PET) The aim of the current project is to evaluate the possibility to enhance the diagnostic accuracy by using the combined 18F-FDG-PET-CT imaging in patients with pancreatic cystic neoplasms by combining PET-CT with MRI and MDCT.

Detailed Description

Today, in clinical practice the diagnosis pancreatic cystic neoplasms are based on MDCT, MRI and ERCP followed by surgical exploration. The information gained by conventional imaging modalities is restricted to the morphological details, which usually is insufficient for the definitive staging of the pancreatic cystic neoplasms. Based on these previous studies, it seems that PET especially combined with CT modality could improve the diagnostic accuracy of the pancreatic cystic lesions. So far, there are only few cases published concerning the role of 18F-FDG-PET-CT in the differential diagnosis of cystic pancreatic lesions. Therefore, more studies are needed to determine the role of combined 18F-FDG-PET-CT in the diagnosis of pancreatic cystic lesions. The aim of the current project is to evaluate the possibility to enhance the diagnostic accuracy by using the combined 18F-FDG-PET-CT imaging in patients with pancreatic cystic neoplasms by combining PET-CT with MRI and MDCT. The study consists of 20-30 patients with pancreatic cystic neoplasms. The patients enrolled in the study will be imaged by MDCT, MRI combined with magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP) and 18F-FDG-PET-CT followed by surgery or follow-up. The data will be collected between 2011 and 2013.

Registry
clinicaltrials.gov
Start Date
March 2011
End Date
January 2014
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • suspicion of pancreatic cystic neoplasm using US, MDCT, MRI and/or ERCP
  • laparotomy planned because of the lesion
  • signed informed consent

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Predictive Value of PET/CT imaging for Identifying Malignant and Benign Pancreatic Cystic Lesions

Time Frame: 1 mo

To determine sensitivities, specificities, accuracy and positive/negative predictive values of PET/CT imaging for differentiating malignant and benign cystic lesions in patients who are to undergo surgical resection.

Secondary Outcomes

  • To compare PET/CT to ERCP, MDCT and MRI-MRCP(1 mo)

Study Sites (1)

Loading locations...

Similar Trials